Cecile Rouleau

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. doi request reprint Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma
    Cecile Rouleau
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 14:7223-36. 2008
  2. ncbi request reprint The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution
    Cecile Rouleau
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 32:739-48. 2008
  3. doi request reprint Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue Framingham, MA 01701 9322, USA
    Microvasc Res 76:180-8. 2008
  4. ncbi request reprint Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 34:619-27. 2009
  5. doi request reprint Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Cancer Ther 7:2536-46. 2008
  6. doi request reprint Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Microvasc Res 82:253-62. 2011
  7. ncbi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009
  8. doi request reprint Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, Massachussetts 01701, USA
    Clin Cancer Res 17:2777-87. 2011
  9. ncbi request reprint Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Microvasc Res 71:163-74. 2006
  10. doi request reprint Endosialin: a novel malignant cell therapeutic target for neuroblastoma
    Cecile Rouleau
    Genzyme Corp, 49 New York Avenue, Framingham, MA 01701, USA
    Int J Oncol 39:841-51. 2011

Detail Information

Publications20

  1. doi request reprint Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma
    Cecile Rouleau
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 14:7223-36. 2008
    ..Endosialin/CD248/tumor endothelial marker 1 is expressed in stromal cells, endothelial cells, and pericytes in various tumors; however, few studies have focused on expression in malignant cells...
  2. ncbi request reprint The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution
    Cecile Rouleau
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 32:739-48. 2008
    ..The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein...
  3. doi request reprint Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue Framingham, MA 01701 9322, USA
    Microvasc Res 76:180-8. 2008
    ..Anti-endosialin antibodies may have value in identifying vasculature in malignant tissues. With the appropriate agent, targeting endosialin may interfere with blood vessel growth during tumor development...
  4. ncbi request reprint Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Int J Oncol 34:619-27. 2009
    ..Endosialin expression by both CAF and MSC further implies the potential contribution of MSC to tumor stroma via differentiation into tumor stromal fibroblasts...
  5. doi request reprint Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Cancer Ther 7:2536-46. 2008
    ..The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC...
  6. doi request reprint Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
    Microvasc Res 82:253-62. 2011
    ..These data demonstrate that TEM-7 is a vascular protein associated with angiogenic states. TEM-7 is a novel and attractive target for antiangiogenic therapy...
  7. ncbi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701, USA
    Int J Oncol 34:1329-40. 2009
    ..Bringing together bone marrow toxicity data, tumor cell line cytotoxicity data, and human tumor xenograft efficacy provides valuable information for the translation of preclinical findings to the clinic...
  8. doi request reprint Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, Massachussetts 01701, USA
    Clin Cancer Res 17:2777-87. 2011
    ....
  9. ncbi request reprint Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy
    Rebecca G Bagley
    Genzyme Corporation, Framingham, MA 01701 9322, USA
    Microvasc Res 71:163-74. 2006
    ..Pericytes displayed invasive action against NSCLC clusters in the absence of other cell types. Perivascular cells contribute to the progression of disease and are an attractive target for anti-angiogenic therapy...
  10. doi request reprint Endosialin: a novel malignant cell therapeutic target for neuroblastoma
    Cecile Rouleau
    Genzyme Corp, 49 New York Avenue, Framingham, MA 01701, USA
    Int J Oncol 39:841-51. 2011
    ..Human neuroblastoma xenograft tumors were found to be positive for endosialin. Our work suggests that endosialin may be a suitable therapeutic target for neuroblastoma...
  11. doi request reprint Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
    Leslie S Kurtzberg
    Genzyme Corporation, Framingham, MA 01701, USA
    Cancer Chemother Pharmacol 64:1029-38. 2009
    ..The bone marrow toxicity and human tumor xenograft activity of three tubulin-binding compounds, vincristine, paclitaxel, and tasidotin were compared...
  12. doi request reprint Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells
    Rebecca G Bagley
    Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
    Cancer Chemother Pharmacol 68:1537-46. 2011
    ..To investigate the activity and myeloprotective properties of erufosine, a novel alkylphosphocholine (APC), on human malignant cells and normal bone marrow cells...
  13. doi request reprint Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
    Leslie S Kurtzberg
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Mol Cancer Ther 7:3212-22. 2008
    ..This may be due to greater sensitivity of human bone marrow than mouse to the cytotoxicity of these agents. It may be possible to achieve similar levels of ARC-111 in patients as in mice allowing improved antitumor activity...
  14. doi request reprint Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling
    Cecile Rouleau
    Genzyme Corporation, Framingham, MA, USA
    Int J Oncol 39:73-89. 2011
    ..These results demonstrate for the first time that endosialin is a suitable therapeutic target for poor prognosis and advanced disease...
  15. ncbi request reprint Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function
    Cecile Rouleau
    Genzyme Corp, 1 Mountain Road, Framingham, MA 01701, USA
    Mol Cancer Ther 5:219-29. 2006
    ..These results indicate that PRL-3 is functional in both endothelial cells and malignant cells and further validate PRL-3 as a potentially important molecular target for anticancer therapy...
  16. ncbi request reprint Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy
    Rebecca G Bagley
    Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
    Cancer Res 65:9741-50. 2005
    ..These results support the notion that pericytes and EPC contribute to malignancy and that these cell types can be useful as cell-based models for tumor vascular development and selection of agents that may provide therapeutic benefit...
  17. pmc Characteristics of human Ewing/PNET sarcoma models
    Beverly A Teicher
    Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
    Ann Saudi Med 31:174-82. 2011
    ..Ewing PNET sarcomas are a rare disease where models are available...
  18. ncbi request reprint Murine endothelial cell lines as models of tumor endothelial cells
    Jennifer Walter-Yohrling
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Clin Cancer Res 10:2179-89. 2004
    ..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds...
  19. pmc Vascular gene expression in nonneoplastic and malignant brain
    Stephen L Madden
    Genetics and Genomics, 5 Mountain Rd, Framingham, MA 01701, USA
    Am J Pathol 165:601-8. 2004
    ..Additional characterization of this extensive brain endothelial cell gene expression database will provide unique molecular insights into vascular gene expression...
  20. ncbi request reprint Troponin I inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptor
    Laurie Feldman
    Laboratory for Cell and Molecular Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Microvasc Res 63:41-9. 2002
    ..Preliminary data suggest that TnI may be competing with bFGF for interaction with the bFGF receptor on responsive cells...